Transarterial chemoembolization: Modalities, indication, and patient selection

Transarterial chemoembolization (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma (BCLC B). Further improvement of the use of TACE was the subject of intense clinical research over the past years. The introduction of DEB-TACE brought more technical standard...

Full description

Saved in:

Bibliographic Details
Published in	Journal of hepatology Vol. 62; no. 5; pp. 1187 - 1195
Main Authors	Sieghart, Wolfgang, Hucke, Florian, Peck-Radosavljevic, Markus
Format	Journal Article
Language	English
Published	Netherlands Elsevier B.V 01.05.2015
Subjects	Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - surgery Chemoembolization, Therapeutic - adverse effects Chemoembolization, Therapeutic - methods Gastroenterology and Hepatology HCC Hepatocellular carcinoma Humans Intermediate stage Liver - diagnostic imaging Liver Neoplasms - pathology Liver Neoplasms - surgery mRECIST Outcome Assessment (Health Care) Overall survival Patient Selection Prognosis Radiography Response Risk Adjustment TACE Response mRECIST TACE HCC Hepatocellular carcinoma Overall survival Patient selection Intermediate stage
Online Access	Get full text
ISSN	0168-8278 1600-0641 1600-0641
DOI	10.1016/j.jhep.2015.02.010

Cover

Loading…

Abstract	Transarterial chemoembolization (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma (BCLC B). Further improvement of the use of TACE was the subject of intense clinical research over the past years. The introduction of DEB-TACE brought more technical standardization and reduction of TACE related toxicity. The use of dynamic radiologic response evaluation criteria (EASL, mRECIST), uncovered the prognostic significance of objective tumor response. Finally, new approaches for better patient selection for initial and subsequent TACE treatment schedules will limit the use of TACE to some extent but have the potential to improve outcome for patients at risk for TACE-induced harm.
AbstractList	Transarterial chemoembolization (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma (BCLC B). Further improvement of the use of TACE was the subject of intense clinical research over the past years. The introduction of DEB-TACE brought more technical standardization and reduction of TACE related toxicity. The use of dynamic radiologic response evaluation criteria (EASL, mRECIST), uncovered the prognostic significance of objective tumor response. Finally, new approaches for better patient selection for initial and subsequent TACE treatment schedules will limit the use of TACE to some extent but have the potential to improve outcome for patients at risk for TACE-induced harm. Transarterial chemoembolization (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma (BCLC B). Further improvement of the use of TACE was the subject of intense clinical research over the past years. The introduction of DEB-TACE brought more technical standardization and reduction of TACE related toxicity. The use of dynamic radiologic response evaluation criteria (EASL, mRECIST), uncovered the prognostic significance of objective tumor response. Finally, new approaches for better patient selection for initial and subsequent TACE treatment schedules will limit the use of TACE to some extent but have the potential to improve outcome for patients at risk for TACE-induced harm.Transarterial chemoembolization (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma (BCLC B). Further improvement of the use of TACE was the subject of intense clinical research over the past years. The introduction of DEB-TACE brought more technical standardization and reduction of TACE related toxicity. The use of dynamic radiologic response evaluation criteria (EASL, mRECIST), uncovered the prognostic significance of objective tumor response. Finally, new approaches for better patient selection for initial and subsequent TACE treatment schedules will limit the use of TACE to some extent but have the potential to improve outcome for patients at risk for TACE-induced harm. Summary Transarterial chemoembolization (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma (BCLC B). Further improvement of the use of TACE was the subject of intense clinical research over the past years. The introduction of DEB-TACE brought more technical standardization and reduction of TACE related toxicity. The use of dynamic radiologic response evaluation criteria (EASL, mRECIST), uncovered the prognostic significance of objective tumor response. Finally, new approaches for better patient selection for initial and subsequent TACE treatment schedules will limit the use of TACE to some extent but have the potential to improve outcome for patients at risk for TACE-induced harm.
Author	Sieghart, Wolfgang Peck-Radosavljevic, Markus Hucke, Florian
Author_xml	– sequence: 1 givenname: Wolfgang surname: Sieghart fullname: Sieghart, Wolfgang email: wolfgang.sieghart@meduniwien.ac.at – sequence: 2 givenname: Florian surname: Hucke fullname: Hucke, Florian – sequence: 3 givenname: Markus surname: Peck-Radosavljevic fullname: Peck-Radosavljevic, Markus email: markus.peck@meduniwien.ac.at
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/25681552$$D View this record in MEDLINE/PubMed
BookMark	eNqFks1O3TAQhS1EBRfaF-iiypIFScdOnDgIIVWofxKFRenasp1BODj2xc6tRJ--Dhc2SKUr26Nzjj3f-IDs-uCRkPcUKgq0_ThW4y2uKwaUV8AqoLBDVrQFKKFt6C5ZZZEoBevEPjlIaQSAGvpmj-wz3grKOVuRy-uofFJxxmiVK8wtTgEnHZz9o2Yb_EnxIwzK2dliOi6sH6x5rB8Xyg_FOu_Rz0VCh2YpvyVvbpRL-O5pPSS_vny-Pv9WXlx9_X7-6aI0vBdzqQ1XWnUK6p7XtKF1j_lhKATt60Fz02LDBGtr0NB1FHXTGM1Qd2YQusvH-pAcbXPXMdxvMM1yssmgc8pj2CSZG-_6nkPdZumHJ-lGTzjIdbSTig_ymUEWiK3AxJBSxBtp7PzY5ByVdZKCXHDLUS645YJbApMZd7ayF9bn9FdNp1sTZkC_LUaZTKZocLAxU5RDsK_bz17YjbM-j8Xd4QOmMWyiz-gllSkb5M_lEyx_gPI8f9F0OeDk3wH_u_0v6zHBPQ
CitedBy_id	crossref_primary_10_1159_000513404 crossref_primary_10_1002_cld_530 crossref_primary_10_1097_MD_0000000000030875 crossref_primary_10_1186_s40644_019_0282_9 crossref_primary_10_1186_s12885_020_06806_4 crossref_primary_10_1007_s00270_018_2069_y crossref_primary_10_1097_JS9_0000000000000654 crossref_primary_10_2217_fon_2019_0127 crossref_primary_10_1177_2050640617716597 crossref_primary_10_1186_s13244_021_00977_9 crossref_primary_10_7554_eLife_15691 crossref_primary_10_1038_s41419_022_04676_1 crossref_primary_10_2217_hep_2018_0001 crossref_primary_10_1097_JS9_0000000000001872 crossref_primary_10_1155_2017_3682614 crossref_primary_10_1111_hepr_13801 crossref_primary_10_2139_ssrn_4191377 crossref_primary_10_3390_diagnostics13172794 crossref_primary_10_1007_s00270_021_02846_w crossref_primary_10_3389_fonc_2021_576232 crossref_primary_10_1097_JS9_0000000000002043 crossref_primary_10_1002_advs_202410484 crossref_primary_10_3350_cmh_2019_0021n crossref_primary_10_2147_JHC_S452120 crossref_primary_10_1111_jgh_13761 crossref_primary_10_1186_s12885_020_06975_2 crossref_primary_10_1002_admi_202300155 crossref_primary_10_1002_mp_16052 crossref_primary_10_12677_acm_2024_1461769 crossref_primary_10_1097_MEG_0000000000001229 crossref_primary_10_1111_liv_12865 crossref_primary_10_1016_j_ebiom_2018_08_010 crossref_primary_10_2147_JHC_S319920 crossref_primary_10_3390_cancers14143351 crossref_primary_10_1007_s11547_024_01840_9 crossref_primary_10_1007_s00261_024_04490_7 crossref_primary_10_1007_s12672_023_00831_y crossref_primary_10_1016_j_ijnurstu_2020_103641 crossref_primary_10_3389_fonc_2023_1320818 crossref_primary_10_12677_tcm_2024_1311445 crossref_primary_10_1007_s10620_023_08010_3 crossref_primary_10_1016_j_hbpd_2020_12_018 crossref_primary_10_1016_j_esmoop_2021_100129 crossref_primary_10_1016_j_clinre_2021_101814 crossref_primary_10_1016_j_jvir_2017_08_023 crossref_primary_10_3233_CH_168002 crossref_primary_10_1080_00365521_2018_1517277 crossref_primary_10_1038_s41392_024_02012_x crossref_primary_10_1002_lt_24196 crossref_primary_10_1016_j_surg_2021_09_009 crossref_primary_10_1016_j_tranon_2022_101600 crossref_primary_10_1016_j_ijrobp_2019_02_032 crossref_primary_10_7759_cureus_28439 crossref_primary_10_1007_s00270_022_03221_z crossref_primary_10_1007_s12325_023_02449_6 crossref_primary_10_14218_JCTH_2019_00050 crossref_primary_10_3389_fonc_2022_981230 crossref_primary_10_1093_jjco_hyx131 crossref_primary_10_3389_fcell_2022_844013 crossref_primary_10_12688_f1000research_24543_1 crossref_primary_10_3389_fgstr_2023_1270264 crossref_primary_10_2147_JHC_S433409 crossref_primary_10_3748_wjg_v26_i3_324 crossref_primary_10_1007_s10620_020_06384_2 crossref_primary_10_1097_COC_0000000000000619 crossref_primary_10_33590_emjhepatol_10313752 crossref_primary_10_1039_D0NR04592F crossref_primary_10_1016_j_cellimm_2016_03_005 crossref_primary_10_1016_j_eclinm_2022_101816 crossref_primary_10_3390_cancers12040791 crossref_primary_10_1186_s12885_018_4120_4 crossref_primary_10_3390_jpm12030436 crossref_primary_10_1016_j_ejrad_2025_111948 crossref_primary_10_1016_j_ijpharm_2024_124424 crossref_primary_10_1002_adhm_202304488 crossref_primary_10_1007_s12032_016_0827_8 crossref_primary_10_1186_s12951_022_01467_w crossref_primary_10_3390_jcm12237469 crossref_primary_10_1097_MD_0000000000034527 crossref_primary_10_1016_j_jvir_2017_01_014 crossref_primary_10_3389_fphar_2023_1170344 crossref_primary_10_1186_s40644_022_00457_3 crossref_primary_10_1371_journal_pone_0243780 crossref_primary_10_3389_fimmu_2024_1469302 crossref_primary_10_12659_MSM_902901 crossref_primary_10_4103_ua_ua_114_23 crossref_primary_10_2147_JHC_S220978 crossref_primary_10_23736_S2724_5985_21_03087_4 crossref_primary_10_1186_s43055_022_00762_8 crossref_primary_10_1111_jcmm_14197 crossref_primary_10_1007_s00261_020_02559_7 crossref_primary_10_3748_wjg_v26_i6_657 crossref_primary_10_1136_esmoopen_2016_000042 crossref_primary_10_18632_oncotarget_15793 crossref_primary_10_3390_jcm10040713 crossref_primary_10_3748_wjg_v28_i36_5324 crossref_primary_10_1007_s00330_016_4511_3 crossref_primary_10_2147_JHC_S318070 crossref_primary_10_1021_acs_molpharmaceut_7b00336 crossref_primary_10_3389_fonc_2022_843680 crossref_primary_10_35712_aig_v2_i2_42 crossref_primary_10_1002_cam4_7419 crossref_primary_10_1186_s12951_022_01385_x crossref_primary_10_2478_raon_2020_0045 crossref_primary_10_3390_cancers11071024 crossref_primary_10_3389_fonc_2023_1235786 crossref_primary_10_3390_cancers12071914 crossref_primary_10_1016_j_dld_2016_03_031 crossref_primary_10_7567_1347_4065_ab12cb crossref_primary_10_1093_nsr_nwad257 crossref_primary_10_1016_j_clinre_2022_101893 crossref_primary_10_1055_s_0042_1758673 crossref_primary_10_2147_JHC_S412643 crossref_primary_10_1016_j_jddst_2024_105431 crossref_primary_10_5009_gnl230080 crossref_primary_10_1080_00365521_2016_1233579 crossref_primary_10_1097_HC9_0000000000000252 crossref_primary_10_1016_j_suronc_2020_12_002 crossref_primary_10_1186_s12943_024_02136_2 crossref_primary_10_3389_fonc_2024_1371414 crossref_primary_10_3748_wjg_v22_i1_253 crossref_primary_10_3389_fimmu_2024_1430571 crossref_primary_10_4251_wjgo_v13_i4_197 crossref_primary_10_1093_labmed_lmae104 crossref_primary_10_3390_life11080840 crossref_primary_10_3389_fphar_2021_714287 crossref_primary_10_3390_biology13040230 crossref_primary_10_1016_j_redii_2024_100048 crossref_primary_10_1155_2019_8350926 crossref_primary_10_1002_ijgo_12888 crossref_primary_10_1186_s12967_024_05298_1 crossref_primary_10_1016_j_jvir_2017_06_022 crossref_primary_10_1177_20584601211034965 crossref_primary_10_2217_bmm_2017_0129 crossref_primary_10_3748_wjg_v22_i1_221 crossref_primary_10_3390_cancers11111782 crossref_primary_10_1007_s00261_016_0900_y crossref_primary_10_3390_cancers13122984 crossref_primary_10_1002_cam4_2380 crossref_primary_10_1158_1078_0432_CCR_17_2899 crossref_primary_10_1016_j_acra_2021_07_029 crossref_primary_10_1016_j_jhep_2019_01_013 crossref_primary_10_2174_0118715206313132240712101607 crossref_primary_10_2217_hep_2017_0009 crossref_primary_10_1186_s12885_019_6386_6 crossref_primary_10_3390_biomedicines12071432 crossref_primary_10_1055_s_0041_1735631 crossref_primary_10_1159_000512028 crossref_primary_10_3390_jcm14020314 crossref_primary_10_1016_j_jvir_2018_08_026 crossref_primary_10_5493_wjem_v6_i1_21 crossref_primary_10_1148_rg_220022 crossref_primary_10_1111_his_14317 crossref_primary_10_3389_fmed_2022_1051113 crossref_primary_10_4254_wjh_v11_i9_689 crossref_primary_10_1007_s11427_022_2142_3 crossref_primary_10_1007_s00270_020_02534_1 crossref_primary_10_1055_s_0044_1787835 crossref_primary_10_12677_ACM_2024_143710 crossref_primary_10_3389_fmolb_2020_609322 crossref_primary_10_1016_j_crad_2018_08_002 crossref_primary_10_1007_s00270_017_1681_6 crossref_primary_10_1177_1533033820965587 crossref_primary_10_1016_j_rgmx_2022_01_006 crossref_primary_10_1007_s40846_023_00826_8 crossref_primary_10_1038_s41416_024_02684_w crossref_primary_10_51894_001c_8983 crossref_primary_10_1080_09205063_2021_1990472 crossref_primary_10_3389_fonc_2022_1005571 crossref_primary_10_1016_j_jimed_2020_10_006 crossref_primary_10_1155_2022_6203817 crossref_primary_10_1136_bmjopen_2023_074245 crossref_primary_10_3390_biomimetics7020077 crossref_primary_10_4329_wjr_v13_i10_314 crossref_primary_10_1016_j_clinre_2021_101777 crossref_primary_10_37349_etat_2023_00167 crossref_primary_10_1093_gastro_goz040 crossref_primary_10_3904_kjim_2019_344 crossref_primary_10_1016_j_jvir_2022_12_466 crossref_primary_10_1097_MEG_0000000000000764 crossref_primary_10_1007_s00432_022_04107_w crossref_primary_10_1080_10717544_2021_1895908 crossref_primary_10_3390_diagnostics11010122 crossref_primary_10_1080_15384047_2021_2020059 crossref_primary_10_1007_s00432_023_04883_z crossref_primary_10_1016_j_jceh_2025_102505 crossref_primary_10_17998_jlc_19_2_159 crossref_primary_10_1097_MD_0000000000026414 crossref_primary_10_1177_26317745211020279 crossref_primary_10_1039_D1NR01394G crossref_primary_10_1371_journal_pone_0269941 crossref_primary_10_1055_s_0042_1754361 crossref_primary_10_1007_s11912_015_0494_5 crossref_primary_10_3390_cancers14071634 crossref_primary_10_1136_spcare_2022_003870 crossref_primary_10_1007_s00330_023_09390_w crossref_primary_10_1016_j_jhep_2023_02_032 crossref_primary_10_1016_j_ijbiomac_2023_123160 crossref_primary_10_1007_s00261_024_04676_z crossref_primary_10_1016_j_actbio_2022_07_019 crossref_primary_10_3390_cells12151930 crossref_primary_10_1007_s11684_017_0546_3 crossref_primary_10_1007_s12029_022_00832_0 crossref_primary_10_3389_fmolb_2021_662366 crossref_primary_10_1007_s11547_024_01906_8 crossref_primary_10_1016_j_jhep_2022_09_006 crossref_primary_10_1016_j_cld_2024_08_003 crossref_primary_10_3390_gastroent15010006 crossref_primary_10_1002_jmri_27143 crossref_primary_10_3390_cancers13040812 crossref_primary_10_1007_s00535_020_01711_w crossref_primary_10_1097_MD_0000000000038174 crossref_primary_10_1016_j_mtbio_2023_100927 crossref_primary_10_4103_tcmj_tcmj_84_21 crossref_primary_10_1200_JCO_22_00020 crossref_primary_10_1038_sigtrans_2016_47 crossref_primary_10_3390_diagnostics12061308 crossref_primary_10_1016_j_ejso_2021_09_017 crossref_primary_10_1007_s00595_017_1603_x crossref_primary_10_1186_s12885_024_11978_4 crossref_primary_10_1016_j_annpat_2024_10_004 crossref_primary_10_1016_j_ejrad_2020_108966 crossref_primary_10_1016_j_rgmxen_2022_01_004 crossref_primary_10_1159_000517735 crossref_primary_10_1200_JCO_22_00392 crossref_primary_10_1111_jpi_12900 crossref_primary_10_3389_fonc_2023_1129065 crossref_primary_10_1016_j_jrras_2024_101111 crossref_primary_10_1001_jamasurg_2023_5909 crossref_primary_10_1155_2017_5198798 crossref_primary_10_1016_j_acra_2015_08_021 crossref_primary_10_1007_s00261_020_02701_5 crossref_primary_10_1111_liv_14220 crossref_primary_10_3389_fbioe_2021_761548 crossref_primary_10_1007_s10238_022_00889_y crossref_primary_10_1016_j_acra_2022_12_031 crossref_primary_10_3892_ol_2024_14244 crossref_primary_10_1007_s00330_017_5145_9 crossref_primary_10_1007_s11547_019_01076_y crossref_primary_10_2147_JHC_S400948
Cites_doi	10.1093/annonc/mds225 10.1016/j.jhep.2011.04.028 10.1111/j.1440-1746.2011.06963.x 10.1055/s-0030-1247133 10.1016/j.dld.2013.01.012 10.1016/j.jhep.2011.08.017 10.1016/j.jhep.2013.08.022 10.1007/s00330-011-2118-2 10.1002/hep.24246 10.1148/radiol.12111550 10.1007/s00508-011-0033-9 10.1016/0016-5085(88)90436-2 10.1038/bjc.2014.199 10.1016/j.jhep.2013.01.039 10.1055/s-0030-1247132 10.1055/s-2007-1007122 10.1016/j.jhep.2012.01.008 10.1002/hep.27290 10.1097/SLA.0000000000000236 10.1002/hep.510290145 10.1016/j.jhep.2011.10.021 10.1016/j.ejrad.2012.12.009 10.1038/bjc.2013.85 10.1053/j.gastro.2004.09.032 10.1001/jama.2010.262 10.3322/caac.20107 10.1016/j.ejca.2008.10.027 10.1002/hep.20933 10.1111/j.1600-6143.2007.01965.x 10.1016/S0168-8278(01)00130-1 10.1016/j.jvir.2012.12.013 10.1001/jama.2012.385 10.1111/jgh.12452 10.1007/s00270-006-0062-3 10.1158/1078-0432.CCR-12-2721 10.1002/cncr.24050 10.1016/S1470-2045(08)70284-5 10.1093/jnci/92.3.205 10.1016/j.jhep.2011.12.001 10.1007/s00270-009-9750-0 10.1016/j.jhep.2006.10.020 10.1007/s00270-012-0394-0 10.1016/j.jhep.2014.01.014 10.1093/annonc/mdt247 10.1016/j.jhep.2014.07.002 10.1148/radiol.12112264 10.1056/NEJM199505113321903 10.1016/j.jvir.2009.10.038 10.1053/jhep.2002.33156 10.1093/annonc/mds605 10.1016/j.jhep.2012.07.025 10.1200/JCO.2013.49.5283 10.1002/hep.24199 10.1038/nrclinonc.2014.122 10.1002/hep.24670 10.1148/radiol.2241011262 10.1016/S0168-8278(98)80187-6 10.1111/liv.12314 10.1053/jhep.2003.50047 10.1007/s00270-009-9711-7 10.1016/j.ctrv.2010.07.006 10.1002/hep.26000 10.1016/S0168-8278(14)60131-8 10.1148/radiol.11110282 10.1002/hep.510270617 10.1016/j.jhep.2012.06.014 10.1016/S0140-6736(02)08649-X 10.1093/jnci/djn134 10.1016/0168-8278(90)90110-D 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 10.1016/j.jhep.2011.03.007 10.1002/hep.26256 10.1158/1078-0432.CCR-12-3796
ContentType	Journal Article
Copyright	2015 European Association for the Study of the Liver European Association for the Study of the Liver Copyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Copyright_xml	– notice: 2015 European Association for the Study of the Liver – notice: European Association for the Study of the Liver – notice: Copyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
DBID	6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/j.jhep.2015.02.010
DatabaseName	ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1600-0641
EndPage	1195
ExternalDocumentID	25681552 10_1016_j_jhep_2015_02_010 S0168827815000847 1_s2_0_S0168827815000847
Genre	Research Support, Non-U.S. Gov't Journal Article Review
GroupedDBID	--- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29K 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 D-I DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDZ HMK HMO HVGLF HX~ HZ~ IHE J1W KOM LZ1 M27 M41 MJL MO0 N9A O-L O9- OAUVE OC. ON0 OVD OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K TEORI UV1 WUQ X7M YOC Z5R ZGI ~G- AACTN AFCTW AFKWA AJOXV AMFUW RIG 6I. AAFTH AAIAV ABLVK ABYKQ AHPSJ AJBFU EFLBG LCYCR AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8
ID	FETCH-LOGICAL-c598t-bc5aba7a0395314139e094e88193db5c6e4282630b0771eb44cb2eb7cd8b7eb43
IEDL.DBID	.~1
ISSN	0168-8278 1600-0641
IngestDate	Fri Jul 11 10:48:00 EDT 2025 Thu Apr 03 06:57:37 EDT 2025 Tue Jul 01 02:22:01 EDT 2025 Thu Apr 24 23:09:10 EDT 2025 Fri Feb 23 02:28:47 EST 2024 Sun Feb 23 10:19:19 EST 2025 Tue Aug 26 19:50:59 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	5
Keywords	Response mRECIST TACE HCC Hepatocellular carcinoma Overall survival Patient selection Intermediate stage
Language	English
License	This is an open access article under the CC BY-NC-ND license. Copyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c598t-bc5aba7a0395314139e094e88193db5c6e4282630b0771eb44cb2eb7cd8b7eb43
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
OpenAccessLink	https://www.sciencedirect.com/science/article/pii/S0168827815000847
PMID	25681552
PQID	1687995036
PQPubID	23479
PageCount	9
ParticipantIDs	proquest_miscellaneous_1687995036 pubmed_primary_25681552 crossref_citationtrail_10_1016_j_jhep_2015_02_010 crossref_primary_10_1016_j_jhep_2015_02_010 elsevier_sciencedirect_doi_10_1016_j_jhep_2015_02_010 elsevier_clinicalkeyesjournals_1_s2_0_S0168827815000847 elsevier_clinicalkey_doi_10_1016_j_jhep_2015_02_010
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	2015-05-01
PublicationDateYYYYMMDD	2015-05-01
PublicationDate_xml	– month: 05 year: 2015 text: 2015-05-01 day: 01
PublicationDecade	2010
PublicationPlace	Netherlands
PublicationPlace_xml	– name: Netherlands
PublicationTitle	Journal of hepatology
PublicationTitleAlternate	J Hepatol
PublicationYear	2015
Publisher	Elsevier B.V
Publisher_xml	– name: Elsevier B.V
References	Verslype, Rosmorduc, Rougier (b0095) 2012; 23 Bruix, Llovet, Castells, Montana, Bru, Ayuso (b0045) 1998; 27 Nicolini, Martinetti, Crespi, Maggioni, Sangiovanni (b0125) 2010; 21 Terzi, Golfieri, Piscaglia, Galassi, Dazzi, Leoni (b0345) 2012; 57 Park, Sherman, Colombo, Roberts, Schwartz, Degos (b0160) 2012; 30 Marelli, Stigliano, Triantos, Senzolo, Cholongitas, Davies (b0080) 2007; 30 Xavier, Guillaume Penaranda, Castellani, Perrier, Pol, Monnet (b0390) 2013; 58 Cheng, Amarapurkar, Chao, Chen, Geschwind, Goh (b0365) 2014; 34 Pelletier, Ducreux, Gay, Luboinski, Hagege, Dao (b0065) 1998; 29 Llovet, Di Bisceglie, Bruix, Kramer, Lencioni, Zhu (b0280) 2008; 100 Shim, Lee, Won, Shin, Kim, Lim (b0305) 2012; 56 Oliveri, Wetterslev, Gluud (b0100) 2011 Takayasu, Arii, Kudo, Ichida, Matsui, Izumi (b0190) 2012; 56 Kadalayil, Benini, Pallan, O’Beirne, Marelli, Yu (b0235) 2013; 24 Golfieri, Renzulli, Mosconi, Forlani, Giampalma, Piscaglia (b0340) 2013; 24 Sieghart, Hucke, Pinter, Graziadei, Vogel, Muller (b0380) 2013; 57 Forner, Gilabert, Bruix, Raoul (b0220) 2014; 11 Georgiades, Geschwind, Harrison, Hines-Peralta, Liapi, Hong (b0325) 2012; 265 Bargellini, Bozzi, Campani, Carrai, De Simone, Pollina (b0350) 2013; 82 Malagari, Pomoni, Moschouris, Bouma, Koskinas, Stefaniotou (b0185) 2012; 35 Hucke, Sieghart, Schoniger-Hekele, Peck-Radosavljevic, Muller (b0030) 2011; 123 Shim, Lee, Kim, Shin, Kim, Lim (b0300) 2012; 262 Therasse, Arbuck, Eisenhauer, Wanders, Kaplan, Rubinstein (b0250) 2000; 92 Bogaerts, Ford, Sargent, Schwartz, Rubinstein, Lacombe (b0270) 2009; 45 Bruix, Raoul, Sherman, Mazzaferro, Bolondi, Craxi (b0210) 2012; 57 Gillmore, Stuart, Kirkwood, Hameeduddin, Woodward, Burroughs (b0285) 2011; 55 Yao, Xiao, Bass, Kerlan, Ascher, Roberts (b0200) 2007; 7 Meyer, Kirkwood, Roughton, Beare, Tsochatzis, Yu (b0090) 2013; 108 Golfieri, Cappelli, Cucchetti, Piscaglia, Carpenzano, Peri (b0355) 2011; 53 Prajapati, Spivey, Hanish, El-Rayes, Kauh, Chen (b0295) 2013; 24 Forner, Llovet, Bruix (b0105) 2012; 56 Lin, Liaw, Lee, Lai (b0055) 1988; 94 Bruix, Sherman, Llovet, Beaugrand, Lencioni, Burroughs (b0260) 2001; 35 Forner, Reig, de Lope, Bruix (b0010) 2010; 30 Burrel, Reig, Forner, Barrufet, de Lope, Tremosini (b0180) 2012; 56 Lo, Ngan, Tso, Liu, Lam, Poon (b0060) 2002; 35 Choi, Shim, Shin, Kim, Lim, Lee (b0330) 2014; 60 Lammer, Malagari, Vogl, Pilleul, Denys, Watkinson (b0130) 2010; 33 Sherman M, Colombo M, Roberts L, Schwartz M, Degos F, Chen P-J, et al. Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC bridge study: First characterization of the full study population. In: Book of abstracts – ILCA annual conference 2012;abstr. #0-011. Hepatocellulaire GdEedTdC (b0050) 1995; 332 Riaz, Miller, Kulik, Nikolaidis, Yaghmai, Lewandowski (b0320) 2010; 303 Golfieri, Giampalma, Renzulli, Cioni, Bargellini, Bartolozzi (b0135) 2014; 111 Llovet, Bruix (b0040) 2003; 37 Bruix, Sala, Llovet (b0145) 2004; 127 Bolondi, Burroughs, Dufour, Galle, Mazzaferro, Piscaglia (b0170) 2012; 32 Ha, Shim, Kim, Kim, Lim, Lee (b0225) 2014; 29 Pelletier, Roche, Ink, Anciaux, Derhy, Rougier (b0070) 1990; 11 Alberts, Sargent, Nair, Mahoney, Mooney, Thibodeau (b0215) 2012; 307 Bolondi, Cillo, Colombo (b0150) 2013; 45 Malagari, Pomoni, Kelekis, Pomoni, Dourakis, Spyridopoulos (b0085) 2010; 33 Bruix, Sherman (b0265) 2005; 42 Bouvier, Ozenne, Aube, Boursier, Vullierme, Thouveny (b0115) 2011; 21 Llovet, Bustamante, Castells, Vilana, Ayuso Mdel, Sala (b0140) 1999; 29 Forner, Ayuso, Varela, Rimola, Hessheimer, de Lope (b0255) 2009; 115 Giobbie-Hurder, Gelber, Regan (b0335) 2013; 31 Camma, Schepis, Orlando, Albanese, Shahied, Trevisani (b0075) 2002; 224 Mazzaferro, Llovet, Miceli, Bhoori, Schiavo, Mariani (b0195) 2009; 10 Rose, Kikolski, Gish, Kono, Loomba, Hemming (b0110) 2013; 57 Zhong, Ke, Gong, Xiang, Ma, Ye (b0205) 2014; 260 Kim, Park, Joo, Jung, An, Woo (b0360) 2012; 27 Bruix, Reig, Rimola, Forner, Burrel, Vilana (b0370) 2011; 54 Llovet, Bru, Bruix (b0015) 1999; 19 Jung, Kim, Yoon, Lee, Lee, Suh (b0290) 2013; 58 Raoul, Sangro, Forner, Mazzaferro, Piscaglia, Bolondi (b0175) 2011; 37 (b0020) 2012; 56 Pinter, Hucke, Graziadei, Vogel, Maieron, Konigsberg (b0155) 2012; 263 Lencioni (b0315) 2013; 19 Hucke, Pinter, Graziadei, Vogel, Trauner, Sieghart (b0230) 2014; 60 Hucke, Pinter, Graziadei, Bota, Vogel, Muller (b0240) 2014 Varela, Real, Burrel, Forner, Sala, Brunet (b0120) 2007; 46 Lencioni, Llovet, Han, Tak, Yang, Leberre (b0375) 2012; 30 Kim, Kim, Kim, Kim, Kim do, Park (b0310) 2013; 19 Hucke, Sieghart, Pinter, Graziadei, Vogel, Muller (b0385) 2014; 60 Bruix, Sherman (b0025) 2011; 53 Miller, Hoogstraten, Staquet, Winkler (b0245) 1981; 47 Llovet, Real, Montana, Planas, Coll, Aponte (b0035) 2002; 359 Lencioni, Llovet (b0275) 2010; 30 Jemal, Bray, Center, Ferlay, Ward, Forman (b0005) 2011; 61 Kudo, Han, Finn, Poon, Blanc, Yan (b0395) 2014; 60 Forner (10.1016/j.jhep.2015.02.010_b0255) 2009; 115 Shim (10.1016/j.jhep.2015.02.010_b0300) 2012; 262 Bogaerts (10.1016/j.jhep.2015.02.010_b0270) 2009; 45 Jung (10.1016/j.jhep.2015.02.010_b0290) 2013; 58 Bargellini (10.1016/j.jhep.2015.02.010_b0350) 2013; 82 Bruix (10.1016/j.jhep.2015.02.010_b0260) 2001; 35 Golfieri (10.1016/j.jhep.2015.02.010_b0135) 2014; 111 Lencioni (10.1016/j.jhep.2015.02.010_b0375) 2012; 30 (10.1016/j.jhep.2015.02.010_b0020) 2012; 56 Llovet (10.1016/j.jhep.2015.02.010_b0035) 2002; 359 Zhong (10.1016/j.jhep.2015.02.010_b0205) 2014; 260 Bruix (10.1016/j.jhep.2015.02.010_b0145) 2004; 127 Xavier (10.1016/j.jhep.2015.02.010_b0390) 2013; 58 Riaz (10.1016/j.jhep.2015.02.010_b0320) 2010; 303 Llovet (10.1016/j.jhep.2015.02.010_b0015) 1999; 19 Takayasu (10.1016/j.jhep.2015.02.010_b0190) 2012; 56 Gillmore (10.1016/j.jhep.2015.02.010_b0285) 2011; 55 Llovet (10.1016/j.jhep.2015.02.010_b0280) 2008; 100 Bolondi (10.1016/j.jhep.2015.02.010_b0150) 2013; 45 Pinter (10.1016/j.jhep.2015.02.010_b0155) 2012; 263 Hepatocellulaire GdEedTdC (10.1016/j.jhep.2015.02.010_b0050) 1995; 332 Marelli (10.1016/j.jhep.2015.02.010_b0080) 2007; 30 Lo (10.1016/j.jhep.2015.02.010_b0060) 2002; 35 Kim (10.1016/j.jhep.2015.02.010_b0360) 2012; 27 Bouvier (10.1016/j.jhep.2015.02.010_b0115) 2011; 21 Varela (10.1016/j.jhep.2015.02.010_b0120) 2007; 46 Forner (10.1016/j.jhep.2015.02.010_b0105) 2012; 56 Alberts (10.1016/j.jhep.2015.02.010_b0215) 2012; 307 Golfieri (10.1016/j.jhep.2015.02.010_b0340) 2013; 24 Prajapati (10.1016/j.jhep.2015.02.010_b0295) 2013; 24 Rose (10.1016/j.jhep.2015.02.010_b0110) 2013; 57 Kim (10.1016/j.jhep.2015.02.010_b0310) 2013; 19 Georgiades (10.1016/j.jhep.2015.02.010_b0325) 2012; 265 Meyer (10.1016/j.jhep.2015.02.010_b0090) 2013; 108 Pelletier (10.1016/j.jhep.2015.02.010_b0070) 1990; 11 Hucke (10.1016/j.jhep.2015.02.010_b0385) 2014; 60 Nicolini (10.1016/j.jhep.2015.02.010_b0125) 2010; 21 Kadalayil (10.1016/j.jhep.2015.02.010_b0235) 2013; 24 Mazzaferro (10.1016/j.jhep.2015.02.010_b0195) 2009; 10 Oliveri (10.1016/j.jhep.2015.02.010_b0100) 2011 Bruix (10.1016/j.jhep.2015.02.010_b0045) 1998; 27 Golfieri (10.1016/j.jhep.2015.02.010_b0355) 2011; 53 Llovet (10.1016/j.jhep.2015.02.010_b0140) 1999; 29 Forner (10.1016/j.jhep.2015.02.010_b0220) 2014; 11 Lin (10.1016/j.jhep.2015.02.010_b0055) 1988; 94 Burrel (10.1016/j.jhep.2015.02.010_b0180) 2012; 56 Malagari (10.1016/j.jhep.2015.02.010_b0085) 2010; 33 Bruix (10.1016/j.jhep.2015.02.010_b0025) 2011; 53 Ha (10.1016/j.jhep.2015.02.010_b0225) 2014; 29 Hucke (10.1016/j.jhep.2015.02.010_b0240) 2014 Therasse (10.1016/j.jhep.2015.02.010_b0250) 2000; 92 10.1016/j.jhep.2015.02.010_b0165 Miller (10.1016/j.jhep.2015.02.010_b0245) 1981; 47 Bolondi (10.1016/j.jhep.2015.02.010_b0170) 2012; 32 Hucke (10.1016/j.jhep.2015.02.010_b0230) 2014; 60 Bruix (10.1016/j.jhep.2015.02.010_b0370) 2011; 54 Bruix (10.1016/j.jhep.2015.02.010_b0265) 2005; 42 Park (10.1016/j.jhep.2015.02.010_b0160) 2012; 30 Lencioni (10.1016/j.jhep.2015.02.010_b0315) 2013; 19 Sieghart (10.1016/j.jhep.2015.02.010_b0380) 2013; 57 Forner (10.1016/j.jhep.2015.02.010_b0010) 2010; 30 Raoul (10.1016/j.jhep.2015.02.010_b0175) 2011; 37 Bruix (10.1016/j.jhep.2015.02.010_b0210) 2012; 57 Giobbie-Hurder (10.1016/j.jhep.2015.02.010_b0335) 2013; 31 Pelletier (10.1016/j.jhep.2015.02.010_b0065) 1998; 29 Lammer (10.1016/j.jhep.2015.02.010_b0130) 2010; 33 Jemal (10.1016/j.jhep.2015.02.010_b0005) 2011; 61 Choi (10.1016/j.jhep.2015.02.010_b0330) 2014; 60 Kudo (10.1016/j.jhep.2015.02.010_b0395) 2014; 60 Lencioni (10.1016/j.jhep.2015.02.010_b0275) 2010; 30 Camma (10.1016/j.jhep.2015.02.010_b0075) 2002; 224 Yao (10.1016/j.jhep.2015.02.010_b0200) 2007; 7 Verslype (10.1016/j.jhep.2015.02.010_b0095) 2012; 23 Hucke (10.1016/j.jhep.2015.02.010_b0030) 2011; 123 Malagari (10.1016/j.jhep.2015.02.010_b0185) 2012; 35 Shim (10.1016/j.jhep.2015.02.010_b0305) 2012; 56 Cheng (10.1016/j.jhep.2015.02.010_b0365) 2014; 34 Llovet (10.1016/j.jhep.2015.02.010_b0040) 2003; 37 Terzi (10.1016/j.jhep.2015.02.010_b0345) 2012; 57
References_xml	– volume: 260 start-page: 329 year: 2014 end-page: 340 ident: b0205 article-title: Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma publication-title: Ann Surg – volume: 30 start-page: 61 year: 2010 end-page: 74 ident: b0010 article-title: Current strategy for staging and treatment: the BCLC update and future prospects publication-title: Semin Liver Dis – volume: 30 start-page: 52 year: 2010 end-page: 60 ident: b0275 article-title: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma publication-title: Semin Liver Dis – volume: 11 start-page: 181 year: 1990 end-page: 184 ident: b0070 article-title: A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma publication-title: J Hepatol – volume: 60 start-page: 1212 year: 2014 end-page: 1218 ident: b0330 article-title: Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma publication-title: J Hepatol – volume: 27 start-page: 1578 year: 1998 end-page: 1583 ident: b0045 article-title: Transarterial embolization publication-title: Hepatology – volume: 23 start-page: vii41 year: 2012 end-page: vii48 ident: b0095 article-title: Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol – volume: 56 start-page: 886 year: 2012 end-page: 892 ident: b0190 article-title: Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines publication-title: J Hepatol – volume: 94 start-page: 453 year: 1988 end-page: 456 ident: b0055 article-title: Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma – A randomized controlled trial publication-title: Gastroenterology – volume: 29 start-page: 62 year: 1999 end-page: 67 ident: b0140 article-title: Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials publication-title: Hepatology – volume: 31 start-page: 2963 year: 2013 end-page: 2969 ident: b0335 article-title: Challenges of guarantee-time bias publication-title: J Clin Oncol – volume: 37 start-page: 212 year: 2011 end-page: 220 ident: b0175 article-title: Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization publication-title: Cancer Treat Rev – volume: 21 start-page: 327 year: 2010 end-page: 332 ident: b0125 article-title: Transarterial chemoembolization with epirubicin-eluting beads publication-title: J Vasc Interv Radiol – volume: 57 start-page: 2261 year: 2013 end-page: 2273 ident: b0380 article-title: The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma publication-title: Hepatology – volume: 19 start-page: 1312 year: 2013 end-page: 1314 ident: b0315 article-title: New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma publication-title: Clin Cancer Res – volume: 30 year: 2012 ident: b0160 article-title: Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC bridge study: First characterization of the full study population publication-title: J Clin Oncol – volume: 53 start-page: 1580 year: 2011 end-page: 1589 ident: b0355 article-title: Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 publication-title: Hepatology – volume: 29 start-page: 129 year: 1998 end-page: 134 ident: b0065 article-title: Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC publication-title: J Hepatol – volume: 35 start-page: 1164 year: 2002 end-page: 1171 ident: b0060 article-title: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma publication-title: Hepatology – reference: Sherman M, Colombo M, Roberts L, Schwartz M, Degos F, Chen P-J, et al. Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC bridge study: First characterization of the full study population. In: Book of abstracts – ILCA annual conference 2012;abstr. #0-011. – volume: 53 start-page: 1020 year: 2011 end-page: 1022 ident: b0025 article-title: Management of hepatocellular carcinoma: an update publication-title: Hepatology – volume: 19 start-page: 1503 year: 2013 end-page: 1511 ident: b0310 article-title: Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization publication-title: Clin Cancer Res – volume: 359 start-page: 1734 year: 2002 end-page: 1739 ident: b0035 article-title: Arterial embolisation or chemoembolisation publication-title: Lancet – volume: 57 start-page: 821 year: 2012 end-page: 829 ident: b0210 article-title: Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial publication-title: J Hepatol – volume: 30 year: 2012 ident: b0375 article-title: Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial publication-title: J Clin Oncol – volume: 56 start-page: 406 year: 2012 end-page: 411 ident: b0305 article-title: Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma publication-title: J Hepatol – volume: 24 start-page: 965 year: 2013 end-page: 973 ident: b0295 article-title: MRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE) publication-title: Ann Oncol – volume: 32 start-page: 348 year: 2012 end-page: 359 ident: b0170 article-title: Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions publication-title: Semin Liver Dis – volume: 45 start-page: 712 year: 2013 end-page: 723 ident: b0150 article-title: Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma publication-title: Dig Liver Dis – volume: 55 start-page: 1309 year: 2011 end-page: 1316 ident: b0285 article-title: EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization publication-title: J Hepatol – volume: 127 start-page: S179 year: 2004 end-page: S188 ident: b0145 article-title: Chemoembolization for hepatocellular carcinoma publication-title: Gastroenterology – volume: 58 start-page: 1229A year: 2013 ident: b0390 article-title: Hepatocellular carcinoma: ART score can predict response after TACE: validation in a large HCC cohort mostly associated with HCV and HBV publication-title: Hepatology – volume: 224 start-page: 47 year: 2002 end-page: 54 ident: b0075 article-title: Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials publication-title: Radiology – year: 2014 ident: b0240 article-title: How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma publication-title: J Hepatol – volume: 58 start-page: 1181 year: 2013 end-page: 1187 ident: b0290 article-title: Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization publication-title: J Hepatol – volume: 46 start-page: 474 year: 2007 end-page: 481 ident: b0120 article-title: Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics publication-title: J Hepatol – volume: 54 start-page: 2238 year: 2011 end-page: 2244 ident: b0370 article-title: Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques publication-title: Hepatology – volume: 332 start-page: 1256 year: 1995 end-page: 1261 ident: b0050 article-title: A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire publication-title: N Engl J Med – volume: 115 start-page: 616 year: 2009 end-page: 623 ident: b0255 article-title: Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? publication-title: Cancer – volume: 57 start-page: 1675 year: 2013 end-page: 1676 ident: b0110 article-title: Society of Interventional Radiology critique and commentary on the Cochrane report on transarterial chemoembolization publication-title: Hepatology – volume: 34 start-page: 174 year: 2014 end-page: 183 ident: b0365 article-title: Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: consensus recommendations and review by an International Expert Panel publication-title: Liver Int – volume: 24 start-page: 509 year: 2013 end-page: 517 ident: b0340 article-title: Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? publication-title: J Vasc Interv Radiol – volume: 82 start-page: e212 year: 2013 end-page: e218 ident: b0350 article-title: Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants publication-title: Eur J Radiol – start-page: CD004787 year: 2011 ident: b0100 article-title: Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma publication-title: Cochrane Database Syst Rev – volume: 24 start-page: 2565 year: 2013 end-page: 2570 ident: b0235 article-title: A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular Cancer publication-title: Ann Oncol – volume: 108 start-page: 1252 year: 2013 end-page: 1259 ident: b0090 article-title: A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation publication-title: Br J Cancer – volume: 111 start-page: 255 year: 2014 end-page: 264 ident: b0135 article-title: Randomised controlled trial of doxorubicin-eluting beads publication-title: Br J Cancer – volume: 27 start-page: 1051 year: 2012 end-page: 1056 ident: b0360 article-title: Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma publication-title: J Gastroenterol Hepatol – volume: 45 start-page: 248 year: 2009 end-page: 260 ident: b0270 article-title: Individual patient data analysis to assess modifications to the RECIST criteria publication-title: Eur J Cancer – volume: 262 start-page: 708 year: 2012 end-page: 718 ident: b0300 article-title: Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models publication-title: Radiology – volume: 265 start-page: 115 year: 2012 end-page: 123 ident: b0325 article-title: Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? publication-title: Radiology – volume: 19 start-page: 329 year: 1999 end-page: 338 ident: b0015 article-title: Prognosis of hepatocellular carcinoma: the BCLC staging classification publication-title: Semin Liver Dis – volume: 37 start-page: 429 year: 2003 end-page: 442 ident: b0040 article-title: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival publication-title: Hepatology – volume: 56 start-page: 1330 year: 2012 end-page: 1335 ident: b0180 article-title: Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design publication-title: J Hepatol – volume: 21 start-page: 1719 year: 2011 end-page: 1726 ident: b0115 article-title: Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival publication-title: Eur Radiol – volume: 307 start-page: 1383 year: 2012 end-page: 1393 ident: b0215 article-title: Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon Cancer : a randomized trial publication-title: JAMA – volume: 33 start-page: 541 year: 2010 end-page: 551 ident: b0085 article-title: Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma publication-title: Cardiovasc Intervent Radiol – volume: 57 start-page: 1258 year: 2012 end-page: 1267 ident: b0345 article-title: Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand” publication-title: J Hepatol – volume: 61 start-page: 69 year: 2011 end-page: 90 ident: b0005 article-title: Global cancer statistics publication-title: CA Cancer J Clin – volume: 100 start-page: 698 year: 2008 end-page: 711 ident: b0280 article-title: Design and endpoints of clinical trials in hepatocellular carcinoma publication-title: J Natl Cancer Inst – volume: 123 start-page: 542 year: 2011 end-page: 551 ident: b0030 article-title: Clinical characteristics of patients with hepatocellular carcinoma in Austria – Is there a need for a structured screening program? publication-title: Wien Klin Wochenschr – volume: 33 start-page: 41 year: 2010 end-page: 52 ident: b0130 article-title: Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study publication-title: Cardiovasc Intervent Radiol – volume: 11 start-page: 525 year: 2014 end-page: 535 ident: b0220 article-title: Treatment of intermediate-stage hepatocellular carcinoma publication-title: Nat Rev Clin Oncol – volume: 10 start-page: 35 year: 2009 end-page: 43 ident: b0195 article-title: Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis publication-title: Lancet Oncol – volume: 303 start-page: 1062 year: 2010 end-page: 1069 ident: b0320 article-title: Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma publication-title: JAMA – volume: 7 start-page: 2587 year: 2007 end-page: 2596 ident: b0200 article-title: Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging publication-title: Am J Transpl – volume: 60 start-page: 118 year: 2014 end-page: 126 ident: b0385 article-title: The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE publication-title: J Hepatol – volume: 47 start-page: 207 year: 1981 end-page: 214 ident: b0245 article-title: Reporting results of cancer treatment publication-title: Cancer – volume: 60 start-page: 1697 year: 2014 end-page: 1707 ident: b0395 article-title: Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial publication-title: Hepatology – volume: 35 start-page: 421 year: 2001 end-page: 430 ident: b0260 article-title: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver publication-title: J Hepatol – volume: 263 start-page: 590 year: 2012 end-page: 599 ident: b0155 article-title: Advanced-stage hepatocellular carcinoma: transarterial chemoembolization publication-title: Radiology – volume: 30 start-page: 6 year: 2007 end-page: 25 ident: b0080 article-title: Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies publication-title: Cardiovasc Intervent Radiol – volume: 42 start-page: 1208 year: 2005 end-page: 1236 ident: b0265 article-title: Practice Guidelines Committee AAftSoLD, Management of hepatocellular carcinoma publication-title: Hepatology – volume: 35 start-page: 1119 year: 2012 end-page: 1128 ident: b0185 article-title: Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis publication-title: Cardiovasc Intervent Radiol – volume: 56 start-page: 908 year: 2012 end-page: 943 ident: b0020 article-title: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma publication-title: J Hepatol – volume: 60 start-page: 53 year: 2014 ident: b0230 article-title: Validation of the BCLC-B subclassification in an Austrian TACE cohort publication-title: J Hepatol – volume: 92 start-page: 205 year: 2000 end-page: 216 ident: b0250 article-title: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada publication-title: J Natl Cancer Inst – volume: 29 start-page: 787 year: 2014 end-page: 793 ident: b0225 article-title: Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis publication-title: J Gastroenterol Hepatol – volume: 56 start-page: 984 year: 2012 end-page: 986 ident: b0105 article-title: Chemoembolization for intermediate HCC: is there proof of survival benefit? publication-title: J Hepatol – volume: 23 start-page: vii41 year: 2012 ident: 10.1016/j.jhep.2015.02.010_b0095 article-title: Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol doi: 10.1093/annonc/mds225 – volume: 56 start-page: 406 year: 2012 ident: 10.1016/j.jhep.2015.02.010_b0305 article-title: Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma publication-title: J Hepatol doi: 10.1016/j.jhep.2011.04.028 – volume: 27 start-page: 1051 year: 2012 ident: 10.1016/j.jhep.2015.02.010_b0360 article-title: Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma publication-title: J Gastroenterol Hepatol doi: 10.1111/j.1440-1746.2011.06963.x – volume: 30 start-page: 61 year: 2010 ident: 10.1016/j.jhep.2015.02.010_b0010 article-title: Current strategy for staging and treatment: the BCLC update and future prospects publication-title: Semin Liver Dis doi: 10.1055/s-0030-1247133 – volume: 45 start-page: 712 year: 2013 ident: 10.1016/j.jhep.2015.02.010_b0150 article-title: Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma publication-title: Dig Liver Dis doi: 10.1016/j.dld.2013.01.012 – volume: 56 start-page: 984 year: 2012 ident: 10.1016/j.jhep.2015.02.010_b0105 article-title: Chemoembolization for intermediate HCC: is there proof of survival benefit? publication-title: J Hepatol doi: 10.1016/j.jhep.2011.08.017 – volume: 60 start-page: 118 year: 2014 ident: 10.1016/j.jhep.2015.02.010_b0385 article-title: The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE publication-title: J Hepatol doi: 10.1016/j.jhep.2013.08.022 – volume: 21 start-page: 1719 year: 2011 ident: 10.1016/j.jhep.2015.02.010_b0115 article-title: Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival publication-title: Eur Radiol doi: 10.1007/s00330-011-2118-2 – volume: 53 start-page: 1580 year: 2011 ident: 10.1016/j.jhep.2015.02.010_b0355 article-title: Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5cm) hepatocellular carcinomas publication-title: Hepatology doi: 10.1002/hep.24246 – volume: 263 start-page: 590 year: 2012 ident: 10.1016/j.jhep.2015.02.010_b0155 article-title: Advanced-stage hepatocellular carcinoma: transarterial chemoembolization vs. sorafenib publication-title: Radiology doi: 10.1148/radiol.12111550 – volume: 123 start-page: 542 year: 2011 ident: 10.1016/j.jhep.2015.02.010_b0030 article-title: Clinical characteristics of patients with hepatocellular carcinoma in Austria – Is there a need for a structured screening program? publication-title: Wien Klin Wochenschr doi: 10.1007/s00508-011-0033-9 – volume: 94 start-page: 453 year: 1988 ident: 10.1016/j.jhep.2015.02.010_b0055 article-title: Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma – A randomized controlled trial publication-title: Gastroenterology doi: 10.1016/0016-5085(88)90436-2 – volume: 111 start-page: 255 year: 2014 ident: 10.1016/j.jhep.2015.02.010_b0135 article-title: Randomised controlled trial of doxorubicin-eluting beads vs. conventional chemoembolisation for hepatocellular carcinoma publication-title: Br J Cancer doi: 10.1038/bjc.2014.199 – volume: 58 start-page: 1181 year: 2013 ident: 10.1016/j.jhep.2015.02.010_b0290 article-title: Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization publication-title: J Hepatol doi: 10.1016/j.jhep.2013.01.039 – volume: 30 start-page: 52 year: 2010 ident: 10.1016/j.jhep.2015.02.010_b0275 article-title: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma publication-title: Semin Liver Dis doi: 10.1055/s-0030-1247132 – volume: 19 start-page: 329 year: 1999 ident: 10.1016/j.jhep.2015.02.010_b0015 article-title: Prognosis of hepatocellular carcinoma: the BCLC staging classification publication-title: Semin Liver Dis doi: 10.1055/s-2007-1007122 – volume: 56 start-page: 1330 year: 2012 ident: 10.1016/j.jhep.2015.02.010_b0180 article-title: Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design publication-title: J Hepatol doi: 10.1016/j.jhep.2012.01.008 – volume: 60 start-page: 1697 year: 2014 ident: 10.1016/j.jhep.2015.02.010_b0395 article-title: Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial publication-title: Hepatology doi: 10.1002/hep.27290 – volume: 260 start-page: 329 year: 2014 ident: 10.1016/j.jhep.2015.02.010_b0205 article-title: Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma publication-title: Ann Surg doi: 10.1097/SLA.0000000000000236 – volume: 29 start-page: 62 year: 1999 ident: 10.1016/j.jhep.2015.02.010_b0140 article-title: Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials publication-title: Hepatology doi: 10.1002/hep.510290145 – volume: 56 start-page: 886 year: 2012 ident: 10.1016/j.jhep.2015.02.010_b0190 article-title: Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines publication-title: J Hepatol doi: 10.1016/j.jhep.2011.10.021 – volume: 82 start-page: e212 year: 2013 ident: 10.1016/j.jhep.2015.02.010_b0350 article-title: Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants publication-title: Eur J Radiol doi: 10.1016/j.ejrad.2012.12.009 – volume: 108 start-page: 1252 year: 2013 ident: 10.1016/j.jhep.2015.02.010_b0090 article-title: A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs. embolisation alone for hepatocellular carcinoma publication-title: Br J Cancer doi: 10.1038/bjc.2013.85 – volume: 127 start-page: S179 year: 2004 ident: 10.1016/j.jhep.2015.02.010_b0145 article-title: Chemoembolization for hepatocellular carcinoma publication-title: Gastroenterology doi: 10.1053/j.gastro.2004.09.032 – volume: 303 start-page: 1062 year: 2010 ident: 10.1016/j.jhep.2015.02.010_b0320 article-title: Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma publication-title: JAMA doi: 10.1001/jama.2010.262 – volume: 61 start-page: 69 year: 2011 ident: 10.1016/j.jhep.2015.02.010_b0005 article-title: Global cancer statistics publication-title: CA Cancer J Clin doi: 10.3322/caac.20107 – volume: 45 start-page: 248 year: 2009 ident: 10.1016/j.jhep.2015.02.010_b0270 article-title: Individual patient data analysis to assess modifications to the RECIST criteria publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.10.027 – volume: 42 start-page: 1208 year: 2005 ident: 10.1016/j.jhep.2015.02.010_b0265 article-title: Practice Guidelines Committee AAftSoLD, Management of hepatocellular carcinoma publication-title: Hepatology doi: 10.1002/hep.20933 – volume: 30 issue: Suppl. 4; abstr. LBA154 year: 2012 ident: 10.1016/j.jhep.2015.02.010_b0375 article-title: Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial publication-title: J Clin Oncol – volume: 7 start-page: 2587 year: 2007 ident: 10.1016/j.jhep.2015.02.010_b0200 article-title: Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging publication-title: Am J Transpl doi: 10.1111/j.1600-6143.2007.01965.x – volume: 35 start-page: 421 year: 2001 ident: 10.1016/j.jhep.2015.02.010_b0260 article-title: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver publication-title: J Hepatol doi: 10.1016/S0168-8278(01)00130-1 – volume: 24 start-page: 509 year: 2013 ident: 10.1016/j.jhep.2015.02.010_b0340 article-title: Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? publication-title: J Vasc Interv Radiol doi: 10.1016/j.jvir.2012.12.013 – volume: 58 start-page: 1229A issue: S1 year: 2013 ident: 10.1016/j.jhep.2015.02.010_b0390 article-title: Hepatocellular carcinoma: ART score can predict response after TACE: validation in a large HCC cohort mostly associated with HCV and HBV publication-title: Hepatology – volume: 307 start-page: 1383 year: 2012 ident: 10.1016/j.jhep.2015.02.010_b0215 article-title: Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon Cancer : a randomized trial publication-title: JAMA doi: 10.1001/jama.2012.385 – volume: 29 start-page: 787 year: 2014 ident: 10.1016/j.jhep.2015.02.010_b0225 article-title: Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis publication-title: J Gastroenterol Hepatol doi: 10.1111/jgh.12452 – volume: 30 start-page: 6 year: 2007 ident: 10.1016/j.jhep.2015.02.010_b0080 article-title: Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies publication-title: Cardiovasc Intervent Radiol doi: 10.1007/s00270-006-0062-3 – volume: 19 start-page: 1503 year: 2013 ident: 10.1016/j.jhep.2015.02.010_b0310 article-title: Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-2721 – volume: 115 start-page: 616 year: 2009 ident: 10.1016/j.jhep.2015.02.010_b0255 article-title: Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? publication-title: Cancer doi: 10.1002/cncr.24050 – volume: 32 start-page: 348 year: 2012 ident: 10.1016/j.jhep.2015.02.010_b0170 article-title: Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions publication-title: Semin Liver Dis – volume: 10 start-page: 35 year: 2009 ident: 10.1016/j.jhep.2015.02.010_b0195 article-title: Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis publication-title: Lancet Oncol doi: 10.1016/S1470-2045(08)70284-5 – volume: 92 start-page: 205 year: 2000 ident: 10.1016/j.jhep.2015.02.010_b0250 article-title: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada publication-title: J Natl Cancer Inst doi: 10.1093/jnci/92.3.205 – volume: 56 start-page: 908 year: 2012 ident: 10.1016/j.jhep.2015.02.010_b0020 article-title: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma publication-title: J Hepatol doi: 10.1016/j.jhep.2011.12.001 – volume: 33 start-page: 541 year: 2010 ident: 10.1016/j.jhep.2015.02.010_b0085 article-title: Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma publication-title: Cardiovasc Intervent Radiol doi: 10.1007/s00270-009-9750-0 – volume: 46 start-page: 474 year: 2007 ident: 10.1016/j.jhep.2015.02.010_b0120 article-title: Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics publication-title: J Hepatol doi: 10.1016/j.jhep.2006.10.020 – volume: 35 start-page: 1119 year: 2012 ident: 10.1016/j.jhep.2015.02.010_b0185 article-title: Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis publication-title: Cardiovasc Intervent Radiol doi: 10.1007/s00270-012-0394-0 – volume: 60 start-page: 1212 year: 2014 ident: 10.1016/j.jhep.2015.02.010_b0330 article-title: Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma publication-title: J Hepatol doi: 10.1016/j.jhep.2014.01.014 – volume: 24 start-page: 2565 year: 2013 ident: 10.1016/j.jhep.2015.02.010_b0235 article-title: A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular Cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdt247 – year: 2014 ident: 10.1016/j.jhep.2015.02.010_b0240 article-title: How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma publication-title: J Hepatol doi: 10.1016/j.jhep.2014.07.002 – volume: 265 start-page: 115 year: 2012 ident: 10.1016/j.jhep.2015.02.010_b0325 article-title: Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? publication-title: Radiology doi: 10.1148/radiol.12112264 – volume: 332 start-page: 1256 year: 1995 ident: 10.1016/j.jhep.2015.02.010_b0050 article-title: A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire publication-title: N Engl J Med doi: 10.1056/NEJM199505113321903 – volume: 21 start-page: 327 year: 2010 ident: 10.1016/j.jhep.2015.02.010_b0125 article-title: Transarterial chemoembolization with epirubicin-eluting beads vs. transarterial embolization before liver transplantation for hepatocellular carcinoma publication-title: J Vasc Interv Radiol doi: 10.1016/j.jvir.2009.10.038 – volume: 35 start-page: 1164 year: 2002 ident: 10.1016/j.jhep.2015.02.010_b0060 article-title: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma publication-title: Hepatology doi: 10.1053/jhep.2002.33156 – volume: 30 issue: Suppl.; abstr. 4033 year: 2012 ident: 10.1016/j.jhep.2015.02.010_b0160 article-title: Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC bridge study: First characterization of the full study population publication-title: J Clin Oncol – volume: 24 start-page: 965 year: 2013 ident: 10.1016/j.jhep.2015.02.010_b0295 article-title: MRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE) publication-title: Ann Oncol doi: 10.1093/annonc/mds605 – volume: 57 start-page: 1258 year: 2012 ident: 10.1016/j.jhep.2015.02.010_b0345 article-title: Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand” publication-title: J Hepatol doi: 10.1016/j.jhep.2012.07.025 – volume: 31 start-page: 2963 year: 2013 ident: 10.1016/j.jhep.2015.02.010_b0335 article-title: Challenges of guarantee-time bias publication-title: J Clin Oncol doi: 10.1200/JCO.2013.49.5283 – volume: 53 start-page: 1020 year: 2011 ident: 10.1016/j.jhep.2015.02.010_b0025 article-title: Management of hepatocellular carcinoma: an update publication-title: Hepatology doi: 10.1002/hep.24199 – volume: 11 start-page: 525 year: 2014 ident: 10.1016/j.jhep.2015.02.010_b0220 article-title: Treatment of intermediate-stage hepatocellular carcinoma publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2014.122 – volume: 54 start-page: 2238 year: 2011 ident: 10.1016/j.jhep.2015.02.010_b0370 article-title: Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques publication-title: Hepatology doi: 10.1002/hep.24670 – volume: 224 start-page: 47 year: 2002 ident: 10.1016/j.jhep.2015.02.010_b0075 article-title: Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials publication-title: Radiology doi: 10.1148/radiol.2241011262 – volume: 29 start-page: 129 year: 1998 ident: 10.1016/j.jhep.2015.02.010_b0065 article-title: Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC publication-title: J Hepatol doi: 10.1016/S0168-8278(98)80187-6 – volume: 34 start-page: 174 year: 2014 ident: 10.1016/j.jhep.2015.02.010_b0365 article-title: Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: consensus recommendations and review by an International Expert Panel publication-title: Liver Int doi: 10.1111/liv.12314 – volume: 37 start-page: 429 year: 2003 ident: 10.1016/j.jhep.2015.02.010_b0040 article-title: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival publication-title: Hepatology doi: 10.1053/jhep.2003.50047 – volume: 33 start-page: 41 year: 2010 ident: 10.1016/j.jhep.2015.02.010_b0130 article-title: Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study publication-title: Cardiovasc Intervent Radiol doi: 10.1007/s00270-009-9711-7 – volume: 37 start-page: 212 year: 2011 ident: 10.1016/j.jhep.2015.02.010_b0175 article-title: Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2010.07.006 – volume: 57 start-page: 1675 year: 2013 ident: 10.1016/j.jhep.2015.02.010_b0110 article-title: Society of Interventional Radiology critique and commentary on the Cochrane report on transarterial chemoembolization publication-title: Hepatology doi: 10.1002/hep.26000 – volume: 60 start-page: 53 year: 2014 ident: 10.1016/j.jhep.2015.02.010_b0230 article-title: Validation of the BCLC-B subclassification in an Austrian TACE cohort publication-title: J Hepatol doi: 10.1016/S0168-8278(14)60131-8 – volume: 262 start-page: 708 year: 2012 ident: 10.1016/j.jhep.2015.02.010_b0300 article-title: Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models publication-title: Radiology doi: 10.1148/radiol.11110282 – volume: 27 start-page: 1578 year: 1998 ident: 10.1016/j.jhep.2015.02.010_b0045 article-title: Transarterial embolization vs. symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution publication-title: Hepatology doi: 10.1002/hep.510270617 – volume: 57 start-page: 821 year: 2012 ident: 10.1016/j.jhep.2015.02.010_b0210 article-title: Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial publication-title: J Hepatol doi: 10.1016/j.jhep.2012.06.014 – volume: 359 start-page: 1734 year: 2002 ident: 10.1016/j.jhep.2015.02.010_b0035 article-title: Arterial embolisation or chemoembolisation vs. symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(02)08649-X – volume: 100 start-page: 698 year: 2008 ident: 10.1016/j.jhep.2015.02.010_b0280 article-title: Design and endpoints of clinical trials in hepatocellular carcinoma publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djn134 – volume: 11 start-page: 181 year: 1990 ident: 10.1016/j.jhep.2015.02.010_b0070 article-title: A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma publication-title: J Hepatol doi: 10.1016/0168-8278(90)90110-D – volume: 47 start-page: 207 year: 1981 ident: 10.1016/j.jhep.2015.02.010_b0245 article-title: Reporting results of cancer treatment publication-title: Cancer doi: 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 – volume: 55 start-page: 1309 year: 2011 ident: 10.1016/j.jhep.2015.02.010_b0285 article-title: EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization publication-title: J Hepatol doi: 10.1016/j.jhep.2011.03.007 – volume: 57 start-page: 2261 year: 2013 ident: 10.1016/j.jhep.2015.02.010_b0380 article-title: The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma publication-title: Hepatology doi: 10.1002/hep.26256 – ident: 10.1016/j.jhep.2015.02.010_b0165 – start-page: CD004787 year: 2011 ident: 10.1016/j.jhep.2015.02.010_b0100 article-title: Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma publication-title: Cochrane Database Syst Rev – volume: 19 start-page: 1312 year: 2013 ident: 10.1016/j.jhep.2015.02.010_b0315 article-title: New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-3796
SSID	ssj0003094
Score	2.5817816
SecondaryResourceType	review_article
Snippet	Transarterial chemoembolization (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma (BCLC B). Further improvement of... Summary Transarterial chemoembolization (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma (BCLC B). Further...
SourceID	proquest pubmed crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	1187
SubjectTerms	Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - surgery Chemoembolization, Therapeutic - adverse effects Chemoembolization, Therapeutic - methods Gastroenterology and Hepatology HCC Hepatocellular carcinoma Humans Intermediate stage Liver - diagnostic imaging Liver Neoplasms - pathology Liver Neoplasms - surgery mRECIST Outcome Assessment (Health Care) Overall survival Patient Selection Prognosis Radiography Response Risk Adjustment TACE
Title	Transarterial chemoembolization: Modalities, indication, and patient selection
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S0168827815000847 https://www.clinicalkey.es/playcontent/1-s2.0-S0168827815000847 https://dx.doi.org/10.1016/j.jhep.2015.02.010 https://www.ncbi.nlm.nih.gov/pubmed/25681552 https://www.proquest.com/docview/1687995036
Volume	62
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZS8QwEB5EQXwRb9eLCr5p3V5pUt9kUdZjF_EA30LTpKhou7i7r_52Z9p0RbzAp9KQIe10MvOlmfkCsIeOMc_yTLthrrmLCFy7qRfmLteeDmOeeKY67q3Xj7t30fk9u5-CTlMLQ2mV1vfXPr3y1ralbbXZHjw-tm8QrCA85MInTn90slTBHnGy8sO3jzSP0Essv7dwqbctnKlzvJ4eDHFW-qzi7aQq2u-D00_gswpCpwswb9Gjc1w_4CJMmWIJZnt2f3wZ-lXoqdI00a4c_CAvpXlR5bOttjxyeqUm5I3r4wOHtqvrP3YHTlpox3KsOsPqbBxsXoG705PbTte1Jya4GUvEyFUZS1XKUdsJzi2MT4nB1zcCw36oFctig6uNIA495XHuGxVFmQqM4pkWiuNtuArTRVmYdXAMimueR9iKCCDwFBMIRVIjAiVybGiB36hKZpZOnE61eJZN3tiTJPVKUq_0AonqbcH-RGZQk2n82jtsvoBsykTRsUn09b9K8e-kzNDOzaH05RB7yi_20wI2kfxkgn-OuNuYh8S5SRsuaWHKMY4UC-LbQ5DQgrXabibvHRDzG2PBxj9H3YQ5uqtzL7dgevQ6NtuIj0Zqp5oAOzBz3Lm-vKLr2UW3_w5oDw8A
linkProvider	Elsevier
linkToHtml	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT8MwDLbGkIAL4s14Fokbq9bH0qTcEAIN9riwSbtFTZOKTdBObPv_OG1aCQFD4tg0VlrHsb829heAa3SMSZzE0vYTSW1E4NKOHD-xqXSkH9DQUflxb_1B0Bm1n8dkXIP7shZGp1Ua31_49Nxbm5aW0WZrNpm0XhCsIDykzNWc_uhk12Bds1OROqzfPXU7g8oh-05oKL6ZrQVM7UyR5jV9VZq20iU5dacupP05Pv2GP_M49LgD2wZAWnfFM-5CTaV7sNE3W-T7MMijT56piaZl4Zy8Z-pdZG-m4PLW6mdSg2_8RG5aese6-GnXtKJUWoZm1Zrnx-Ng8wGMHh-G9x3bHJpgxyRkC1vEJBIRRYWHuLwwRIUKX18xjPy-FCQOFH5weIHvCIdSV4l2OxaeEjSWTFC89A-hnmapOgZLobikSRtbEQR4jiAM0UikmCdYgg0NcEtV8dgwiuuDLd54mTo25Vq9XKuXOx5H9TbgppKZFXwaK3v75QzwslIUfRtHd79Siv4kpeZmec65y-fYk38zoQaQSvKLFf454lVpHhyXp95ziVKVLXGkgGnKPcQJDTgq7KZ6b0-TvxHinfxz1EvY7Az7Pd57GnRPYUvfKVIxz6C--Fiqc4RLC3FhlsMnLIAQHA
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Transarterial+chemoembolization%3A+Modalities%2C+indication%2C+and+patient+selection&rft.jtitle=Journal+of+hepatology&rft.au=Sieghart%2C+Wolfgang&rft.au=Hucke%2C+Florian&rft.au=Peck-Radosavljevic%2C+Markus&rft.date=2015-05-01&rft.pub=Elsevier+B.V&rft.issn=0168-8278&rft.eissn=1600-0641&rft.volume=62&rft.issue=5&rft.spage=1187&rft.epage=1195&rft_id=info:doi/10.1016%2Fj.jhep.2015.02.010&rft.externalDocID=S0168827815000847
thumbnail_m	http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01688278%2FS0168827815X00031%2Fcov150h.gif